Janssen Pharmaceutica NV

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies (2023) Mcgonagle D, Mcinnes IBB, Deodhar A, Schett G, Shawi M, Chakravarty SDD, Kollmeier APP, et al. Journal article Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naive Adults with PsA (2022) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty S, et al. Conference contribution GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY (2022) Rahman P, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Cua D, et al. Conference contribution IMMUNOLOGICAL DIFFERENCES BETWEEN PSA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS (2022) Siebert S, Coates L, Schett G, Raychaudhuri SP, Chen W, Gao S, Chakravarty SD, et al. Conference contribution Time to evolve: predicting engineered T cell-associated toxicity with next-generation models (2022) Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, et al. Journal article, Review article LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al. Journal article Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial (2022) Terpos E, Dimopoulos MA, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, et al. Journal article Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2) (2022) Schett G, Loza MJ, Palanichamy A, Fitzgerald O, Ritchlin C, Bay-Jensen AC, Nielsen SH, et al. Journal article Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2) (Rheumatology and Therapy, (2022), 10.1007/s40744-022-00444-x) (2022) Schett G, Loza MJ, Palanichamy A, Fitzgerald O, Ritchlin C, Bay-Jensen AC, Nielsen SH, et al. Journal article, Erratum Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, et al. Journal article